Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies (Details)

v3.22.1
Commitments and Contingencies (Details)
1 Months Ended 12 Months Ended
Nov. 02, 2021
USD ($)
Nov. 02, 2021
GBP (£)
Nov. 11, 2020
Jul. 01, 2020
Nov. 11, 2019
USD ($)
Mar. 14, 2019
USD ($)
Jun. 07, 2018
USD ($)
May 13, 2018
USD ($)
Nov. 22, 2021
Oct. 29, 2021
USD ($)
shares
Aug. 27, 2021
USD ($)
shares
Apr. 29, 2021
USD ($)
Mar. 30, 2021
shares
Feb. 25, 2021
USD ($)
Feb. 17, 2020
USD ($)
Feb. 17, 2020
GBP (£)
Sep. 27, 2019
USD ($)
Sep. 27, 2019
GBP (£)
Mar. 22, 2019
USD ($)
Feb. 26, 2019
USD ($)
Sep. 18, 2018
Aug. 20, 2018
shares
Jul. 25, 2018
USD ($)
Oct. 17, 2017
USD ($)
shares
Dec. 31, 2021
USD ($)
Dec. 31, 2021
GBP (£)
Dec. 31, 2021
CAD ($)
Dec. 31, 2020
USD ($)
shares
Dec. 31, 2020
GBP (£)
Dec. 31, 2019
USD ($)
Nov. 02, 2021
GBP (£)
Sep. 30, 2021
shares
Sep. 03, 2021
USD ($)
Sep. 03, 2021
GBP (£)
Jul. 31, 2021
shares
Feb. 18, 2021
USD ($)
Feb. 18, 2021
GBP (£)
Nov. 06, 2020
shares
Sep. 08, 2020
shares
Jun. 12, 2020
shares
Feb. 17, 2020
GBP (£)
Jan. 01, 2020
USD ($)
Oct. 17, 2018
USD ($)
May 08, 2018
USD ($)
Commitments and Contingencies (Details) [Line Items]                                                                                        
Legal expenses                                                 $ 250,000                                      
Principal amount                                                 371,178                                      
Additional amount                                                 300,000                                      
Interest accruing                                                 6,776,686                                      
Shares issued to settle transaction fee (in Shares) | shares                                                       1,519,628       467,123     150,000     150,000 100,000 250,000        
Settlement paying amount                                                 200,000                                      
Commitments combined amount                                                 3,460,584   $ 4,395,000                                  
Additional sum of amount                                                 2,721,036                                      
Common stock to EarlyBird valued                                               $ 1,973,250                                        
Accounts payable                                                       $ 48,908                                
Accrued expenses                                                       370,000                                
Research and development expenses                                                 $ 443,151     442,453                                
Agreement period     20 years                                           2 years 2 years 2 years                                  
Research and development expenses                                                 $ 2,947,536     75,633                                
Recorded interest expense                                                 0                                      
Account payable                                                 586,611     8,529,259                                
Accrued expense                                                 49,755     14,418                                
Payment of first milestone                                                                 $ 97,900 £ 70,546                    
Past patent costs $ 66,223                                                           £ 49,207                          
Initial License fee 13,458 £ 10,000                                                                                    
Annual maintenance fee $ 4,037 £ 3,000                                                                                    
Common shares (in Shares) | shares                                           9,000,000                                            
Rent                             $ 5,801 £ 4,250                                                        
Total lease commitment                             $ 83,532                                                   £ 61,200      
Security deposit                                                                       $ 6,961 £ 5,100              
Rent expense                                                 $ 0     38,831 £ 30,257                              
Percentage of consultant bonus                         50.00%                                                              
Shares issues (in Shares) | shares                     61,535   100,699                                                              
Financing transaction of agreement                     $ 15,000,000                                                                  
Restricted common stock value                       $ 50,000                                                                
Shares of license agreement                       $ 5,423                                                                
Additional consideration agreement, description                           As additional consideration for the CEO agreeing to enter into the agreement, the Company awarded him options to purchase 1,400,000 shares of the Company’s common stock, which have a term of 10 years, and an exercise price of $4.43 per share (the closing sales price on the date the board of directors approved the grant (February 26, 2021)). The options as subject to the Company’s 2020 Omnibus Incentive Plan and vest at the rate of (a) 1/5th of such options on the grant date; and (b) 4/5th of such options vesting ratably on a monthly basis over the following 36 months on the last day of each calendar month; provided, however, that such options vest immediately upon the CEO’s death or disability, termination without cause or a termination by the CEO for good reason (as defined in the agreement), a change in control of the Company or upon a sale of the Company.                                                              
Salary available to paid bonus                                                 45.00% 45.00% 45.00%                                  
Accrued Bonus                                                 $ 205,500                                      
Purchase shares (in Shares) | shares                   275,000                                                                    
Percentage of targeted amount                   50.00%                                                                    
Yissum [Member]                                                                                        
Commitments and Contingencies (Details) [Line Items]                                                                                        
Related party transaction, description                                                 The Company shall pay Yissum the following amounts in connection with the achievement of the following milestones:  ●Submission of the first Investigational New Drug application: $75,000  ●Dosing of first patient in phase II trial: $100,000  ●Dosing of first patient in phase Ill trial: $150,000  ●Upon first market authorization/clearance: $150,000  ●Upon second market authorization/clearance: $75,000  ●For every $250,000,000.00 US in accumulated Net Sales of the Product until $1,000,000,000.00 US in sales: $250,000 Upon the commercialization of the license, the Company shall pay Yissum a royalty equal to 3% of the first aggregate $500,000,000 of annual net sales and 5% thereafter. As of December 31, 2021, the Company had no balances in accounts payable and accrued expenses, respectively, relating to the Additional Yissum Agreement; as of December 31, 2020, the Company had $91,748 and $298,686 of accounts payable and accrued expenses, respectively, relating to the Additional Yissum Agreement. During the years ended December 31, 2021 and 2020, the Company recorded the purchase of the patents of $0 and $72,995, respectively, as an intangible asset to be amortized on a straight-line basis over the remaining lives of the patents and $246,753 and $477,411, respectively, of research and development expenses.  The Company shall pay Yissum the following amounts in connection with the achievement of the following milestones:  ●Submission of the first Investigational New Drug application: $75,000  ●Dosing of first patient in phase II trial: $100,000  ●Dosing of first patient in phase Ill trial: $150,000  ●Upon first market authorization/clearance: $150,000  ●Upon second market authorization/clearance: $75,000  ●For every $250,000,000.00 US in accumulated Net Sales of the Product until $1,000,000,000.00 US in sales: $250,000 Upon the commercialization of the license, the Company shall pay Yissum a royalty equal to 3% of the first aggregate $500,000,000 of annual net sales and 5% thereafter. As of December 31, 2021, the Company had no balances in accounts payable and accrued expenses, respectively, relating to the Additional Yissum Agreement; as of December 31, 2020, the Company had $91,748 and $298,686 of accounts payable and accrued expenses, respectively, relating to the Additional Yissum Agreement. During the years ended December 31, 2021 and 2020, the Company recorded the purchase of the patents of $0 and $72,995, respectively, as an intangible asset to be amortized on a straight-line basis over the remaining lives of the patents and $246,753 and $477,411, respectively, of research and development expenses.  The Company shall pay Yissum the following amounts in connection with the achievement of the following milestones:  ●Submission of the first Investigational New Drug application: $75,000  ●Dosing of first patient in phase II trial: $100,000  ●Dosing of first patient in phase Ill trial: $150,000  ●Upon first market authorization/clearance: $150,000  ●Upon second market authorization/clearance: $75,000  ●For every $250,000,000.00 US in accumulated Net Sales of the Product until $1,000,000,000.00 US in sales: $250,000 Upon the commercialization of the license, the Company shall pay Yissum a royalty equal to 3% of the first aggregate $500,000,000 of annual net sales and 5% thereafter. As of December 31, 2021, the Company had no balances in accounts payable and accrued expenses, respectively, relating to the Additional Yissum Agreement; as of December 31, 2020, the Company had $91,748 and $298,686 of accounts payable and accrued expenses, respectively, relating to the Additional Yissum Agreement. During the years ended December 31, 2021 and 2020, the Company recorded the purchase of the patents of $0 and $72,995, respectively, as an intangible asset to be amortized on a straight-line basis over the remaining lives of the patents and $246,753 and $477,411, respectively, of research and development expenses.                                   
ReFormation [Member]                                                                                        
Commitments and Contingencies (Details) [Line Items]                                                                                        
Related party transaction, description       On July 1, 2020, the Company entered into an amended agreement with ReFormation Pharmaceuticals, Corp. (“ReFormation”) and 360 Life Sciences Corp. (“360”), whereby 360 has entered into an agreement to acquire 100% ownership of ReFormation, on or before July 31, 2020 (“Closing Date”). The Company shares officers and directors with each of ReFormation and 360. Upon the Closing Date, 360 will make tranche payments in tranches to 180 LP in the aggregate amount of $300,000. The parties agree that the obligations will be paid by 360 to 180 LP by payments of $100,000 for every $1,000,000 raised through the financing activities of 360, up to a total of $300,000, however, not less than 10% of all net financing proceeds received by 360 shall be put towards the obligation to the Company until paid in full. This transaction closed on July 31, 2020.                                                                                 
Petcanna Shares [Member]                                                                                        
Commitments and Contingencies (Details) [Line Items]                                                                                        
Related party transaction, description                                           Pursuant to the terms of the Sub-license Agreement, the Company has granted a sub-license on the Licensed Patents to pursue development and commercialization for the treatment of any and all veterinary conditions. In consideration, Petcanna will (a) issue 9,000,000 common shares of its share capital (the “Petcanna Shares”) 30 days after the effective date; and (b) pay royalties of 1% of net sales. The Company will be issued 85% and Yissum will be issued 15% of the 9,000,000 common shares of the Petcanna subsidiary.                                            
EarlyBird Finder’s Fee [Member] | KBL [Member]                                                                                        
Commitments and Contingencies (Details) [Line Items]                                                                                        
Percentage of cash payable                                                                                     1.00%  
liabilities at closing in excess                                                                                     $ 5,000,000  
Cash payments                                               $ 275,000                                        
Restricted common stock shares (in Shares) | shares                                               225,000                                        
Yissum [Member] | CBR [Member]                                                                                        
Commitments and Contingencies (Details) [Line Items]                                                                                        
Underwriting commitments, description               Royalties will be payable to Yissum if sales of any products which use, exploit or incorporate technology covered by the Licensed Patents (“Net Sales”) are US $500,000,000 or greater, calculated at 3% for the first annual $500,000,000 of Net Sales and at 5% of Net Sales thereafter. Pursuant to the Yissum Agreement, if Yissum achieves the following milestones, CBR Pharma will be obligated to make the following payments: i) $75,000 for successful point of care in animals; ii) $75,000 for submission of the first investigational new drug testing; iii) $100,000 for commencement of one phase I/II trial; iv) $150,000 for commencement of one phase III trial; v) $100,000 for each product market authorization/clearance (maximum of $500,000); and vi) $250,000 for every $250,000,000 in accumulated sales of the product until $1,000,000,000 in sales is achieved.                                                                         
Consultants amount               $ 100,000                                                                        
First amendment company paid                                                                                   $ 200,000    
Additional consulting percentage                                                                                   35.00%    
Outstanding balance                                                       418,098                                
Non-refundable license fees         $ 70,000                                                                              
Aggregate fees         398,250                                                                              
Annual license maintenance fee         $ 25,000                                                                              
Evotec [Member] | Katexco [Member]                                                                                        
Commitments and Contingencies (Details) [Line Items]                                                                                        
Minimum Fund             $ 4,937,500                                                                          
Maximum Fund             $ 5,350,250                                                                          
Research and development expenses                                                 $ 0     31,979                                
Recorded interest expense                                                       31,979                                
Unpaid balance                                                 0     1,342,299                                
Stanford [Member]                                                                                        
Commitments and Contingencies (Details) [Line Items]                                                                                        
Related party transaction, description                                             Furthermore, the Company will be obligated to make the following milestone payments: i) $100,000 upon initiation of Phase II trial, ii) $500,000 upon the first U.S. Food and Drug Administration approval of a product (the “Licensed Product”) resulting from the Licensed Patents; and iii) $250,000 upon each new Licensed Product thereafter. The Stanford License Agreement is cancellable by the Company with 30 days’ notice. Royalties, calculated at 2.5% of 95% of net product sales, will be payable to Stanford. Also, the Company will reimburse Stanford for patent expenses as per the agreement. The Company paid Stanford $20,000 for the annual license maintenance fee that was recorded to prepaid expenses and is being expensed on a straight-line basis over 12 months, which had a zero balance as of December 31, 2021. During the years ended December 31, 2021 and 2020, the Company recorded patent and license fees of $78,245 and $32,979, respectively, related to the Stanford License Agreement, which is included in general and administrative expenses on the accompanying statements of operations and comprehensive loss.                                           
Stanford [Member] | Katexco [Member]                                                                                        
Commitments and Contingencies (Details) [Line Items]                                                                                        
Option payment                                                                                       $ 10,000
license maintenance fee                                             $ 20,000                                          
Anniversaries amount                                             $ 40,000                                          
Shares issues (in Shares) | shares                         37,715                                                              
Percentage of consultant additional bonus                         19.00%                                                              
Oxford [Member]                                                                                        
Commitments and Contingencies (Details) [Line Items]                                                                                        
Research and development expenses                                     $ 900,000                                                  
Aggregate value                                                 0     704,960                                
Account payable                                                       693,515                                
Accrued expense                                                       11,445                                
Oxford [Member] | CBR [Member]                                                                                        
Commitments and Contingencies (Details) [Line Items]                                                                                        
Related party transaction, description                                         On September 18, 2020, CBR Pharma entered into a 3 year research and development agreement (the “3 Year Oxford Agreement”) with Oxford to research and investigate the mechanisms underlying fibrosis in exchange for aggregate consideration of $1,085,738 (£795,468), of which $109,192 (£80,000) is to be paid 30 days after the project start date and the remaining amount is to be paid in four equal installments of $244,136 (£178,867) on the six month anniversary and each of the annual anniversaries of the project start date. The agreement can be terminated by either party upon written notice or if the Company remains in default on any payments due under this agreement for more than 30 days. During the year ended December 31, 2021 and 2020, the Company recognized $364,673 (£264,938) and $113,433 (£88,385), respectively, of research and development expenses in connection with the 3 Year Oxford Agreement. On September 21, 2020, CBR Pharma entered into a 2 year research and development agreement (the “2 Year Oxford Agreement”) with Oxford University for the clinical development of cannabinoid drugs for the treatment of inflammatory diseases in exchange for aggregate consideration of $625,124 (£458,000), of which $138,917 (£101,778) is to be paid 30 days after the project start date and the remaining amount is to be paid every 6 months after the project start date in 4 installments, whereby $138,917 (£101,778) is to be paid in the first 3 installments and $69,456 (£50,888) is to be paid as the final installment. The agreement can be terminated by either party upon written notice or if the Company remains in default on any payments due under this agreement for more than 30 days. During the years ended December 31, 2021 and 2020, the Company recognized $139,977 (£101,778) and $78,374 (£61,067) of research and development expenses, respectively, in connection with the 2 Year Oxford Agreement, which is reflected within accrued expenses on the accompanying consolidated balance sheet.                                               
Oxford [Member] | LP [Member]                                                                                        
Commitments and Contingencies (Details) [Line Items]                                                                                        
Research and development expenses                                                       186,391   $ 396,950                            
Kennedy [Member] | LP [Member]                                                                                        
Commitments and Contingencies (Details) [Line Items]                                                                                        
Related party transaction, description                 (i) 1% of the net sales for the first annual GBP £1 million (USD $1,283,400) of net sales, and (ii) 2% of the net sales after the net sales are at or in excess of GBP £1 million, as well as 25% of all sublicense revenue, provided that the amount of such percentage of sublicense revenue based on amounts which constitute royalties shall not be less than 1% on the first cumulative GBP £1 million of net sales of the products sold by such sublicenses or their affiliates, and 2% on that portion of the cumulative net sales of the products sold by such sublicenses or their affiliates in excess of GBP £1 million.The term of the royalties paid by the Company to Kennedy will expire on the later of (i) the last valid claim of a patent included in the Kennedy Licensed Patents which covers or claims the exploitation of a product in the applicable country; (ii) the expiration of regulatory exclusivity for the product in the country; or (iii) 10 years from the first commercial sale of the product in the country. The Kennedy License Agreement may be terminated without cause by providing a 90-day notice.                                                                       
Upfront fee paid for intangible assets                                 $ 74,000 £ 60,000                                                    
Pharmaceutical [Member] | LP [Member]                                                                                        
Commitments and Contingencies (Details) [Line Items]                                                                                        
Negotiation provide                                       $ 1,200,000                                                
Research agreement           $ 1,200,000                                                                            
Phamaceutical agreement           900,000                                     0     240,000                                
One year agreement           $ 300,000                                                                            
Bad debt expense                                                       300,000                                
Income receivable                                                       $ 300,000                                
Fifth Oxford Agreement [Member]                                                                                        
Commitments and Contingencies (Details) [Line Items]                                                                                        
Research and development expenses                                                 210,215 £ 152,848                                    
Prepaid balance                                                 $ 80,852 £ 58,788                                    
Chief Executive Officer [Member]                                                                                        
Commitments and Contingencies (Details) [Line Items]                                                                                        
CEOs annual base salary                           $ 450,000                                                            
Percentage of automatic annual salary increase                           5.00%                                                            
Chief Financial Officer [Member]                                                                                        
Commitments and Contingencies (Details) [Line Items]                                                                                        
Additional consideration agreement, description                           As additional consideration for the CFO agreeing to enter into the agreement, the Company awarded him options to purchase 180,000 shares of the Company’s common stock, which have a term of 10 years, and an exercise price of $4.43 per share (the closing sales price on the date the board of directors approved the grant (February 26, 2021)). The options are subject to the Company’s 2020 Omnibus Incentive Plan and vest at the rate of (a) 1/5th of such options upon the grant date; and (b) 4/5th of such options vesting ratably on a monthly basis over the following 36 months on the last day of each calendar month; provided, however, that such options vest immediately upon the CFO’s death or disability, termination without cause or a termination by the CFO for good reason (as defined in the agreement), a change in control of the Company or upon a sale of the Company.                                                             
Annual base salary                           $ 300,000                                                            
Percentage of salary available to paid bonus                                                 30.00%                                      
Accrued bonus payable                                                 $ 90,000                                      
Chief Operating Officer/Chief Business Officer [Member]                                                                                        
Commitments and Contingencies (Details) [Line Items]                                                                                        
Initial salary                   $ 390,000                                                                    
Initial salary subject to increase completion                   10,000                                                                    
Salary financing                   $ 50,000,000                                                                    
Percentage of start day anniversary                   5.00%                                                                    
IPO [Member]                                                                                        
Commitments and Contingencies (Details) [Line Items]                                                                                        
Issued and outstanding shares                                                 5.00% 5.00% 5.00%                                  
Consulting Agreement [Member]                                                                                        
Commitments and Contingencies (Details) [Line Items]                                                                                        
Related party transaction, description                                                 On February 22, 2021, the Company entered into a consultancy agreement (as amended, the “Consulting Agreement”) with a related party, Prof. Jagdeep Nanchahal (the “Consultant”). The Consulting Agreement was effective December 1, 2020. Pursuant to the Consulting Agreement, the Company agreed to pay the Consultant 15,000 British Pounds (GBP) per month (approximately $20,800) during the term of the agreement, increasing to 23,000 GBP per month (approximately $32,000) on the date (a) of publication of the data from the phase 2b clinical trial for Dupuytren’s Contracture (RIDD) and (b) the date that the Company has successfully raised over $15 million in capital. The Company also agreed to pay the Consultant the following bonus amounts:    ● the sum of £100,000 (approximately $138,000) upon submission of the Dupuytren’s Contracture clinical trial data for publication in a peer-reviewed journal (“Bonus 1”);     ● the sum of £434,673 GBP (approximately $605,000) (“Bonus 2”), which is earned and payable upon the Company raising a minimum of $15 million in additional funding, through the sale of debt or equity, after December 1, 2020 (the “Vesting Date”). Bonus 2 is payable within 30 days of the Vesting Date and shall not be accrued, due or payable prior to the Vesting Date. Bonus 2 is payable, at the election of the Consultant, at least 50% (fifty percent) in shares of the Company’s common stock, at the lower of (i) $3.00 per share, or (ii) the trading price on the date of the grant, with the remainder paid in GBP;     ● the sum of £5,000 (approximately $7,000) on enrollment of the first patient to the phase 2 frozen shoulder trial (“Bonus 3”); and   ●the sum of £5,000 (approximately $7,000) for enrollment of the first patient to the phase 2 delirium/POCD trial (“Bonus 4”). On February 22, 2021, the Company entered into a consultancy agreement (as amended, the “Consulting Agreement”) with a related party, Prof. Jagdeep Nanchahal (the “Consultant”). The Consulting Agreement was effective December 1, 2020. Pursuant to the Consulting Agreement, the Company agreed to pay the Consultant 15,000 British Pounds (GBP) per month (approximately $20,800) during the term of the agreement, increasing to 23,000 GBP per month (approximately $32,000) on the date (a) of publication of the data from the phase 2b clinical trial for Dupuytren’s Contracture (RIDD) and (b) the date that the Company has successfully raised over $15 million in capital. The Company also agreed to pay the Consultant the following bonus amounts:    ● the sum of £100,000 (approximately $138,000) upon submission of the Dupuytren’s Contracture clinical trial data for publication in a peer-reviewed journal (“Bonus 1”);     ● the sum of £434,673 GBP (approximately $605,000) (“Bonus 2”), which is earned and payable upon the Company raising a minimum of $15 million in additional funding, through the sale of debt or equity, after December 1, 2020 (the “Vesting Date”). Bonus 2 is payable within 30 days of the Vesting Date and shall not be accrued, due or payable prior to the Vesting Date. Bonus 2 is payable, at the election of the Consultant, at least 50% (fifty percent) in shares of the Company’s common stock, at the lower of (i) $3.00 per share, or (ii) the trading price on the date of the grant, with the remainder paid in GBP;     ● the sum of £5,000 (approximately $7,000) on enrollment of the first patient to the phase 2 frozen shoulder trial (“Bonus 3”); and   ●the sum of £5,000 (approximately $7,000) for enrollment of the first patient to the phase 2 delirium/POCD trial (“Bonus 4”). On February 22, 2021, the Company entered into a consultancy agreement (as amended, the “Consulting Agreement”) with a related party, Prof. Jagdeep Nanchahal (the “Consultant”). The Consulting Agreement was effective December 1, 2020. Pursuant to the Consulting Agreement, the Company agreed to pay the Consultant 15,000 British Pounds (GBP) per month (approximately $20,800) during the term of the agreement, increasing to 23,000 GBP per month (approximately $32,000) on the date (a) of publication of the data from the phase 2b clinical trial for Dupuytren’s Contracture (RIDD) and (b) the date that the Company has successfully raised over $15 million in capital. The Company also agreed to pay the Consultant the following bonus amounts:    ● the sum of £100,000 (approximately $138,000) upon submission of the Dupuytren’s Contracture clinical trial data for publication in a peer-reviewed journal (“Bonus 1”);     ● the sum of £434,673 GBP (approximately $605,000) (“Bonus 2”), which is earned and payable upon the Company raising a minimum of $15 million in additional funding, through the sale of debt or equity, after December 1, 2020 (the “Vesting Date”). Bonus 2 is payable within 30 days of the Vesting Date and shall not be accrued, due or payable prior to the Vesting Date. Bonus 2 is payable, at the election of the Consultant, at least 50% (fifty percent) in shares of the Company’s common stock, at the lower of (i) $3.00 per share, or (ii) the trading price on the date of the grant, with the remainder paid in GBP;     ● the sum of £5,000 (approximately $7,000) on enrollment of the first patient to the phase 2 frozen shoulder trial (“Bonus 3”); and   ●the sum of £5,000 (approximately $7,000) for enrollment of the first patient to the phase 2 delirium/POCD trial (“Bonus 4”).